All Updates

All Updates

icon
Filter
Product updates
EntheoTech Bioscience opens flagship clinic in Kelowna
Psychedelic Medicine
May 2, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

May 2, 2023

EntheoTech Bioscience opens flagship clinic in Kelowna

Product updates

  • EntheoTech Bioscience, a Canadian bioscience company specializing in psychedelic-assisted therapy (PAT), has opened its flagship clinic in Kelowna, British Columbia. The clinic aims to combine the use of psychedelics with therapy to provide a unique treatment experience for individuals with mental health conditions. Additional clinics are planned to open in Vancouver, Calgary, and Edmonton later this year.

  • EntheoMed, the brand under which the clinics operate, offers intramuscular ketamine-assisted therapy. The therapy is administered by a team of healthcare professionals, including physicians, nurses, psychotherapists, and psychedelic facilitators. 

  • EntheoTech focuses on research and development of natural psilocybin formulas to address chronic pain, mental health conditions, and opioid overuse. Their mission is to provide access to PAT and integrative treatments for depression, anxiety, chronic pain, and PTSD using Health Canada-approved substances like ketamine, psilocybin, and MDMA. The company aims to provide integrative wellness experiences that combine traditional and new medicines.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.